---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-006316"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2025-10-07T23:59:59+00:00"
generated_at: "2026-05-17T04:25:39.747819+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Arbutus announces four abstracts accepted for AASLD, including AB-101 Poster of Distinction

## Summary
- Three abstracts on imdusiran and one on AB-101 accepted for AASLD Liver Meeting Nov 7-11, 2025 in Washington DC.
- Imdusiran integrated safety analysis shows well-tolerated at 60-90 mg Q8W for up to 48 weeks dosing and follow-up.
- Imdusiran may enhance pegylated interferon responsiveness in HBV genotype B/C patients vs historical data.
- AB-101 up to 30 mg QD for 28 days was well tolerated; 83% mean PD-L1 receptor occupancy at 30 mg dose.
- AB-101 abstract selected as Poster of Distinction; data on safety, PK, PD and HBV biomarkers will be presented.

## SEC filing metadata
- accession: 0001171843-25-006316
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2025-10-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184325006316/0001171843-25-006316-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184325006316/f8k_100625.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-006316
- JSON: https://secwatch.observer/filing/0001171843-25-006316.json
- Plain text: https://secwatch.observer/filing/0001171843-25-006316.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.